Mindmed stock price prediction


Mind Medicine Mindmed stock price prediction is an act of determining the future value of Mind Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Mind Medicine’s future price could yield a significant profit.

Stock Price Forecast

The 5 analysts offering 12-month price forecasts for Mind Medicine (MindMed) Inc have a median target of 5.14, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +651.64% increase from the last price of 0.68.


What is the Mind Medicine (mindmed) stock forecast for 2022?

The Mind Medicine (MindMed) stock forecast is 3.1510826660898 USD for 2022 December 25, Sunday. Mind Medicine (MindMed) stock forecast, MMDWF price prediction: Buy or sell Mind Medicine (MindMed) Inc shares?

What does Mind Medicine (mindmed) stock’s P/E ratio mean?

The P/E ratio of Mind Medicine (MindMed) is -8.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Mind Medicine (MindMed) is -8.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Is mindmed stock being forced down?

MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, announced on Dec…. MindMed’s LSD trials are facing a regulatory roadblock but MNMD stock isn’t being forced down.

Should you buy mindmed Inc (mnmd) stock?

The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York. [Read more…] According to 4 analysts, the average rating for MNMD stock is “Buy.”


Is MindMed a good stock?

Mind Medicine (MindMed) has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Will MindMed stock go up?

On average, analysts give MNMD a Strong Buy rating. The average price target is $8, which means analysts expect the stock to gain by 633.94% over the next twelve months. That average ranking earns MNMD an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.

Why is MNMD stock going down?

Summary. The recent decline in MindMed’s share price is a result of changes to the broader macroeconomic landscape. The FDA just approved MindMed’s IND application, inducing a spike in the company’s shares. Still, MindMed is down 67% in the past year.

What time is MindMed on Nasdaq?

MindMed will commence trading on the Nasdaq under the symbol MNMD effective April 27, 2021; until then the Company will continue to trade in the United States under the symbol MMEDF on the OTCQB.

Is MindMed being shorted?

Mind Medicine (MindMed) saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 747,300 shares, a decline of 0.1% from the previous total of 748,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment.

How much will mind medicine be worth?

The market for psychedelic drugs could be worth $10.8 billion by 2027, growing at an annual rate of 12.4% until then, according to ResearchAndMarkets.com.

Should I hold MNMD?

Out of 3 analysts, 2 (66.67%) are recommending MNMD as a Strong Buy, 1 (33.33%) are recommending MNMD as a Buy, 0 (0%) are recommending MNMD as a Hold, 0 (0%) are recommending MNMD as a Sell, and 0 (0%) are recommending MNMD as a Strong Sell.

Is Atai stock a good buy?

Out of 10 analysts, 6 (60%) are recommending ATAI as a Strong Buy, 3 (30%) are recommending ATAI as a Buy, 1 (10%) are recommending ATAI as a Hold, 0 (0%) are recommending ATAI as a Sell, and 0 (0%) are recommending ATAI as a Strong Sell. What is ATAI’s earnings growth forecast for 2022-2024?

When did MNMD go public?

On Tuesday, April 27th, 2021, the MindMed stock started trading on the Nasdaq Capital Market. On the Nasdaq, the stock trades under the ticker symbol MNMD.

What happened to my MindMed stock?

MindMed stock fell Thursday after the psychedelic drug developer said a Swiss ethics committee cleared the company to begin a study on the effects of the hallucinogen mescaline. The study, set to start this month, adds to the research MindMed (MNMD) is conducting on other psychedelic drugs.

Where can I invest in MindMed?

On the US OTC market, MindMed trades under the MMEDF ticker. You can see from the summary table above that both TD Ameritrade and E-Trade allow you to purchase shroom stocks from the United States. In addition, other brokers such as Charles Schwab and Fidelity offer trading of these stocks, often commission-free.

Who invested in MNMD?

star Kevin O’LearyShark Tank star Kevin O’Leary has invested in hundreds of businesses over the years, some on-screen and some off. But few have attracted as much attention as his investment in psychedelic drug company Mind Medicine (MNMD 6.13%), also known as MindMed.

Should I buy or sell Mind Medicine (MindMed) stock right now?

3 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Mind Medicine (MindMed) in the last year. There are curr…

What is Mind Medicine (MindMed)’s stock price forecast for 2022?

3 analysts have issued 12 month price targets for Mind Medicine (MindMed)’s stock. Their forecasts range from 6.00 to 10.00. On average, they antic…

How has Mind Medicine (MindMed)’s stock price performed in 2022?

Mind Medicine (MindMed)’s stock was trading at 1.38 at the beginning of 2022. Since then, MNMD shares have decreased by 42.0% and is now trading at…

How were Mind Medicine (MindMed)’s earnings last quarter?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) issued its quarterly earnings data on Monday, March, 28th. The company reported ($0.04) earnings per sha…

Who are Mind Medicine (MindMed)’s key executives?

Mind Medicine (MindMed)’s management team includes the following people: Mr. Robert Barrow , CEO & Director (Age 33, Pay $708.41k) Dr. Miriam Ha…

Who are some of Mind Medicine (MindMed)’s key competitors?

Some companies that are related to Mind Medicine (MindMed) include USANA Health Sciences (USNA) , Cronos Group (CRON) , Cresco Labs (CRLBF) , T…

What is Mind Medicine (MindMed)’s stock symbol?

Mind Medicine (MindMed) trades on the NASDAQ under the ticker symbol “MNMD.”

Who are Mind Medicine (MindMed)’s major shareholders?

Mind Medicine (MindMed)’s stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.9…

Which major investors are selling Mind Medicine (MindMed) stock?

MNMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Simplex Trading LLC…

Is MIND MEDICINE (MINDMED) Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering ( NASDAQ : MNMD ) stock is to Strong Buy MNMD stock. Out of 3 analysts , 2 ( 66.67% )…

What is MNMD’s earnings growth forecast for 2022-2024?

( NASDAQ : MNMD ) MIND MEDICINE (MINDMED) ‘s forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology indus…

What is MNMD’s revenue growth forecast for 2026-2027?

( NASDAQ : MNMD ) MIND MEDICINE (MINDMED) ‘s forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology indust…

What is MNMD’s forecast return on assets (ROA) for 2022-2025?

(NASDAQ: MNMD) forecast ROA is -65.11%, which is lower than the forecast US Biotechnology industry average of 21.82%.

What is MNMD’s Price Target?

According to 3 Wall Street analyst s that have issued a 1 year MNMD price target, the average MNMD price target is $7.67 , with the highest…

What is MNMD’s Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: MNMD) MIND MEDICINE (MINDMED)’s current Earnings Per Share (EPS) is -$0.24. On average, analysts forecast that MNMD’s EPS will be -$0.19 f…

What is MNMD’s forecast return on equity (ROE) for 2022-2025?

(NASDAQ: MNMD) forecast ROE is -71.02%, which is considered weak.

Historical and forecast chart of Mind Medicine (MindMed) stock

The chart below shows the historical price of Mind Medicine (MindMed) stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast.

Mind Medicine (MindMed) Daily Price Targets

Forecast target price for 02-25-2022: $ 1.17. Positive dynamics for Mind Medicine (MindMed) shares will prevail with possible volatility of 2.798%.

Mind Medicine (MindMed) forecast for this year

An downtrend is forecast for this month with an optimal target price of $ 1.13332. Pessimistic: $1.05. Optimistic: $1.16

Mind Medicine (MindMed) information and performance

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M.

Mind Medicine (MindMed) (MNMD) stock dividend

Mind Medicine (MindMed) last paid dividends on 01/01/1970. The next scheduled payment will be on 02/27/2020. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment.

Stock Price Forecast

The 4 analysts offering 12-month price forecasts for Mind Medicine (MindMed) Inc have a median target of 4.26, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +267.34% increase from the last price of 1.16.

Analyst Recommendations

The current consensus among 4 polled investment analysts is to Buy stock in Mind Medicine (MindMed) Inc. This rating has held steady since October, when it was unchanged from a Buy rating. Move your mouse over past
months for detail

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

Mind Medicine (MindMed) Inc.

Busey Wealth Management Buys Broadcom Inc, Canadian Pacific Railway, Globe Life Inc, Sells ..

Investment company Busey Wealth Management (Current Portfolio) buys Broadcom Inc, Canadian Pacific Railway, Globe Life Inc, BTC iShares U.S.

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the U.S.

MindMed Enrolls First Participant in a Study of its Session Monitoring System

Mind Medicine (MindMed) Inc.

Sara-Bay Financial Buys Cerence Inc, Public Service Enterprise Group Inc, Welltower Inc, Sells ..

Investment company Sara-Bay Financial (Current Portfolio) buys Cerence Inc, Public Service Enterprise Group Inc, Welltower Inc, Oragenics Inc, Veeva Systems Inc, sells Alibaba Group Holding, Unilever PLC, International Paper Co, Paycom Software Inc, Titan Medical Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sara-Bay Financial..

Stephen Hurst Resigns from MindMed Board of Directors

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company’s Board of Directors.

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

Mind Medicine (MindMed) Inc.

Mind Medicine After-Hype Price Prediction Density Analysis

As far as predicting the price of Mind Medicine at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range.

Mind Medicine Estimiated After-Hype Price Volatility

In the context of predicting Mind Medicine’s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Mind Medicine’s historical news coverage. Mind Medicine’s after-hype downside and upside margins for the prediction period are 0.06 and 7.75, respectively.

Mind Medicine Stock Price Prediction Analysis

Have you ever been surprised when a price of a company such as Mind Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mind Medicine backward and forwards among themselves.

Mind Medicine Hype Timeline

Mind Medicine Mindmed is now traded for 1.23. The entity has historical hype elasticity of -0.04 and average elasticity to hype of competition of 0.0. Mind Medicine is expected to decline in value after the next headline with price expected to drop to 1.18. The average volatility ofmedia hypeimpact on the company stock price is over 100%.

Mind Medicine Related Hype Analysis

Having access to credible news sources related to Mind Medicine’s direct competition is more important than ever and may enhance your ability to predict Mind Medicine’s future price movements.

Mind Medicine Additional Predictive Modules

Most predictive techniques to examine Mind Medicine price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Mind Medicine using various technical indicators.

About Mind Medicine Predictive Indicators

The successful prediction of Mind Medicine stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Mind Medicine Mindmed, already reflect all publicly available information.

What is MindMed’s first clinical trial?

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline. What Happened …

Is MNMD stock still being written?

MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments . The post Get a Dose of Innovative Science With Mind Medicine a…

Is MindMed stock getting a boost?

MindMed ( MNMD) stock is getting a boost on Monday following news from the FDA that allows the company to continue development . The post MNMD Stock: The Big News That Has MindMed Investors Psyched Today …

Is MNMD a long term stock?

MNMD stock is positioned for long-term growth as its LSD, MDMA, and Psilocybin-based treatments have a huge addressable mental wellness market. The post MindMed Can Play a Big Role in the Growing Mental…

Does MNMD stock have ups and downs?

Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence. The post Strong Cash Balance Should Provide a Foundation for…

Signals & Forecast

The Mind Medicine (MindMed) Inc. Subordinate stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.

Support, Risk & Stop-loss

Mind Medicine (MindMed) Inc. Subordinate finds support from accumulated volume at $1.17 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

Is Mind Medicine (MindMed) Inc. Subordinate Voting Shares stock A Buy?

Mind Medicine (MindMed) Inc. Subordinate holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Insiders are very negative selling more shares than they are buying in Mind Medicine (MindMed) Inc. Subordinate

In the last 2 trades there were 209.02 thousand shares sold. The last trade was done 8 days ago by Barrow Robert who sold 18.73 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.


Leave a Comment